Ref. Ares(2017)2320564 - 05/05/2017



"Vigilance and Inspection for the Safety of Transfusion, Assisted Reproduction and Transplantation" – VISTART

Document type:

Deliverable May 2017

Version:

This deliverable is part of the Joint Action '696967/VISTART' which has received funding from the European Union's Health Programme (2014-2020). The content of this Deliverable represents the views of the author only and his/her sole responsibility; it can not be considered to reflect the views of the European Commission and /or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for the use that may be made of the information it contains.

Deliverable 5.1 - How to select and prepare SARE cases of didactic value for insertion in the Notify Library - a user guide for Competent Authorities

TABLE OF CONTENTS

1.		3
	1.1 Selection criteria	3
	1.2 What constitutes a Notify record?	5
2.	WORKFLOW AND EDITORIAL PROCESS	5
	2.1 Statement of support, data protection and confidentiality	6
3.	PROPOSING A CASE FOR SUBMISSION IN THE NOTIFY LIBRARY: RECORD TEMPLATE	. 7
	3.1 ADVERSE OCCURRENCE DESCRIPTION	7
	3.2 ADVERSE OCCURRENCE TYPE	7
	3.3 MPHO TYPE	7
	3.4 TIME TO DETECTION	7
	3.5 ALERTING SIGNALS, SYMPTOMS, EVIDENCE OF OCCURRENCE	7
	3.6 ESTIMATED FREQUENCY	8
	3.7 DEMONSTRATION OF IMPUTABILITY OR ROOT CAUSE	8
	3.8 IMPUTABILITY GRADE	8
	3.9 KEYWORDS	8
	3.10 REFERENCES	9
	3.11 EXPERT COMMENTS FOR PUBLICATION	9
	3.12 NOTES	9
4.	ANNEXES	10
	4.1 Notify Library - Statement of support	10
	4.2 Notify Library - Record template	11
	4.3 Notify Library - Adverse occurrence taxonomy	12
	4.4 Notify Library - MPHO taxonomy	16
	4.5 Imputability grade	12
	4.6 Case examples	12

1. INTRODUCTION

Work Package 5 - Part A of VISTART Joint Action (JA) aims at increasing the involvement of European Union (EU) Member State (MS) Competent Authorities (CAs) in the WHO didactic tool developed and managed by CNT: the Notify Library of adverse occurrences in transfusion, transplantation and assisted reproduction (see link: <u>www.notifylibrary.org</u>). The Notify Library is an open access database of reliably documented didactic cases of adverse occurrences arising from the donation, preparation or clinical application of Substances of Human Origin (SoHOs), from donation to follow-up of donors and recipients. Cases are analysed, linked to their source reference (scientific publications, formal vigilance programmes) and regularly updated by editorial groups of international experts in the fields of transplantation, transfusion and assisted reproduction.

The main objective of the Notify Library is to share published vigilance information for teaching purposes as widely as possible, to build knowledge and create awareness. Sharing the lessons learned from adverse outcomes can allow significant process improvements for the greater protection of donors and patients. These benefits apply where the incident occurred but also anywhere else where an identical or similar incident might occur. The purpose of the Notify Library is not to be a register of registries but to be a comprehensive tool, describing all types of reactions or events that might have didactic value and assist in the estimation of risk.

These Guidelines provide instructions to facilitate EU CAs in the selection and analysis of case types with didactic value from their annual SARE reports to the European Commission for insertion in the Notify Library. The Working Group will support MS CAs to use this didactic tool in order to improve their vigilance investigation activities (policy making, risk assessment, unusual donor suitability questions, training, etc). Editorial Groups (EG) of Experts will be asked to each review their topic-specific records for accuracy and to add missing information and expert comments, where possible. The CA that submitted the record will review and approve any comments or information added by the EG before publication.

1.1 Selection criteria

A case is suitable for inclusion in the Notify Library when it:

- offers a description of an adverse occurrence that has caused harm to a donor or a recipient of a substance of human origin (SoHO), or to a fetus or embryo created through gamete or embryo donation, <u>OR</u>
- offers a description of an adverse occurrence has represented a risk of harm, AND
- is reliably documented in the scientific, clinical or legal literature or in a formal vigilance programme, <u>AND</u>
- has **didactic value** (for example: uncommon/unexpected event, unusual signals or severity, assists in the estimation of risk for donation or clinical application, etc.).

Figure 1 summarises the steps from the case selection to its submission to the Notify Library. Examples of "triggers" that could assist CAs to recognise a relevant case with learning points are listed below (at least one trigger should be present). Subsequently, a specific Notify Library search will be useful to decide if the case is suitable for inclusion in the Library's database. You could search by adverse occurrence type, by keyword or by free text. If you consider that the new case provides didactic value that is different to any existing database record, proceed to propose it.




Fig. 1: Steps from the case selection to its submission to the Notify Library

1.2 What constitutes a Notify record?

The description of an adverse occurrence in transfusion, transplantation or assisted reproduction that has been documented in scientific or grey literature or in an official vigilance system and has didactic value constitutes a Notify record. Expert analysis focuses in particular on how the adverse occurrence was recognised and how it is shown to have been associated with the donation, process or clinical application of the SoHO. A unique record ID number will refer to a specific Notify record once linked to its source reference and uploaded in the Notify Library (see Annex 4.6 for case examples). Each record in the Notify Library describes a type of adverse occurrence for one type of substance (Medical Product of Human Origin, MPHO) (Annex 4.6.1). CAs submitting records for inclusion in the Notify Library's database should make two records for the same type of occurrence with the same MPHO if they consider that are substantially different from each other in terms of cause, method of confirmation of imputability or any other factor that is considered to have major didactic value (Annex 4.6.2). Where one record describes many cases, the experts should summarise the findings using ranges, averages, etc. (Annex 4.6.3).

2. WORKFLOW AND EDITORIAL PROCESS

The Notify team will carry out a check of every record for consistency (terminology, spelling, etc.) and will assign it to an EG (there are currently 5: infection transmissions, malignancy transmissions, living donor reactions, process, clinical complications including transfusion reactions not covered by the other groups). All records will be reviewed and approved by the specific EG. <u>A final revision and approval by the CA is requested before publication</u>. Up to that point, all work on pending cases is invisible to the public.

Figure 2 summarises the workflow from the record submission to its publication in the Notify Library. The following sections provide users with more detailed instructions for the operational steps to follow.




Fig. 2: Workflow and editorial process (actions highlighted in red, CAs; in blue, Notify team and Editorial groups)

2.1 Statement of support, data protection and confidentiality

By signing the Notify Library Statement of Support (Annex 4.1) regarding the provision of selected data from your national vigilance system you will officially contribute to the content of the Notify Library. There are two ways of referencing the submitted cases: for CAs who want their report to stay confidential it will be referenced as: "European Union Annual Vigilance Report, year ..."; alternatively, the specific official Health Authority vigilance programme will be specified. <u>The statement of support should be filled just once</u>. Only the deviation from the default referencing option should be highlighted in the reference field of the record template (see also section n. 3.10).

<u>The completed form should be returned by email to notifylibrary@iss.it</u>. CNT and the Notify team will take the responsibility to anonymise, when asked, all stakeholders (CA, hospitals, tissue establishments, blood banks, etc.), and will consider the information provided as confidential data accessible only to Notify experts for editorial work before publication in the Notify Library.

3. PROPOSING A CASE FOR SUBMISSION IN THE NOTIFY LIBRARY: RECORD TEMPLATE

For consistency reasons, and to allow the transfer of information to the editorial tool of the Notify Library website avoiding transcription errors, it is necessary to standardise the way in which the data is presented.

<u>Please refer to the Notify record template (Annex 4.2). The form should be completed in the following fields (*required fields, minimum data set for proposal submission):</u>

3.1 ADVERSE OCCURRENCE DESCRIPTION*

Please enter here a title that describes the type of adverse occurrence you wish to enter, standardising terminology to what you consider most appropriate, using reference dictionaries, such as MESH, wherever possible.

3.2 ADVERSE OCCURRENCE TYPE

please refer to the Adverse Occurrence taxonomy (Annex 4.3) and select the appropriate term for this type of occurrence. If you consider that new categories should be added to the taxonomy for more effective searching, please propose the new category in the NOTES field.

3.3 MPHO TYPE*

Please refer to the MPHO taxonomy (Annex 4.4) and select the appropriate term for this type of substance. If you consider that a new substance type is needed in the taxonomy, please propose the new category in the NOTES field. Where there is a characteristic of the MPHO that is considered important in the occurrence but is not described in the taxonomy (e.g. method of preservation, microbial inactivation or sterilization, etc.) it is very important to include that information in the keywords (see section n. 3.9 below).

3.4 TIME TO DETECTION*

Please enter the time, in minutes, days, months or years from the adverse occurrence to its detection. In case of more than one occurrence is described, please summarise the findings using ranges, averages, etc.

3.5 ALERTING SIGNALS, SYMPTOMS, EVIDENCE OF OCCURRENCE*

Please enter the signs and symptoms that have been described for that occurrence and substance type.

In the case of adverse occurrences that involve 'Risk of Harm' rather than actual harm, you should describe how the occurrence was detected. Spell out any abbreviations, putting the abbreviation in brackets. Standardise terminology to what you consider most appropriate, using reference dictionaries, such as MESH, wherever possible.

3.6 ESTIMATED FREQUENCY*

Please add this information where quantitative data is available and relevant (for example, inserting a number of occurrences per number of interventions). You can also refer to Eurocet and Council of Europe data (for example, SAR rate for particular tissues/ cells per number of transplants of this type of tissue/cell).

Alternatively, since there is a large variation in epidemiology, in levels of system development and in information available across countries, descriptive information without quantitative data may also have didactic value so please give some idea of frequency from your own experience and knowledge even if imprecise, or use a general term such as 'very rare', 'common', etc.

3.7 DEMONSTRATION OF IMPUTABILITY OR ROOT CAUSE*

Please enter free text to describe the methods used to confirm imputability for this type of occurrence. It will be searchable using keywords. Spell out any abbreviations, putting the abbreviation in brackets. Standardise terminology to what you consider most appropriate, using reference dictionaries, such as MESH, wherever possible. In the case of adverse occurrences that involve 'Risk of Harm' rather than actual harm, you should describe what is considered to be the root cause of the adverse occurrence.

3.8 IMPUTABILITY GRADE*

Select a score for imputability from the "Imputability grade" tab of the record template (provided for consultation also in Annex 4.5). Please note that an imputability score is not applicable for occurrences involving Risk of Harm but no actual harm.

3.9 KEYWORDS

Please type one or more keywords for this type of adverse occurrence associated with this type of substance. Include the substance type, the occurrence description, keywords from the 'alerting signals' or 'demonstration of imputability' fields and any other keyword that you think will be useful for free searching. Standardise terminology to what you consider most appropriate, using

reference dictionaries, such as MESH, wherever possible. Please note that the taxonomy does not describe MPHO in great detail; for example, it does not allow the description of how the MPHO is processed or stored, whether it is virally inactivated or if the record refers to autologous, allogeneic, allogeneic-related donation etc. circumstances. Where characteristics such as these are relevant to the occurrence, and you consider that users might search by these attributes, please ensure that they are entered as keywords. The keywords will be linked to this specific adverse occurrence once the record is published by the Notify team.

3.10 REFERENCES

Refer to your published annual vigilance report or, if your SARE report is not published please give the name of the vigilance programme. Alternatively, for CAs who want their report to stay confidential it will be referenced as: "European Union Annual Vigilance Report, year ..." (see also section n. 2.1 and Annex 4.1).

3.11 EXPERT COMMENTS FOR PUBLICATION

Use this space for didactic comments that will appear on the website when the case is uploaded. All editors are strongly encouraged to use this field for comments on a specific adverse occurrence or substance type in terms of latency, alerting signals, demonstration of imputability, etc., or for any other information that comes from their knowledge and experience. This field will be an additional value of the Notify Library since it represents an invaluable didactic information source. Even if you do not add comments in this section, an editor from an EG may add one which you will subsequently be able to check before publication.

3.12 NOTES

You can use this field as a message board for EG members and/or interaction with the Notify team (text NOT for publication).

The completed form should be returned by email to notifylibrary@iss.it

Please record and share all your comments and practical suggestions from your own experience for improvement to this guide!

4. ANNEXES

4.1 Notify Library - Statement of support

	NOTIFY LIBRARY - Statement of Support
	Name of Organisation:
	Status of Organisation (circle one): Governmental national
	Governmental International
	National Holeshonal occety
	International Professional Society Other Non-governmental Organisation
	Mission/Key Objectives of the Organisation
	On behalf of the Organization named above, I declare our support for the Notify Project in its objective to collect and share didactic information on adverse outcomes in transplantation, transfusion and assisted reproduction with the aim of improving safety and quality in these fields.
	As we share this objective, we will:
	 provide expertise, as and when available, to help in the identification, review and editing of documented
	serious adverse reactions and events for inclusion in the Notify Library website (www.notifylibrary.org) hosted
	by the Italian National Transplant Organization (WHO Collaborating Centre for Vigilance of Cells, Tissues and
	Organs);
	 disseminate the Notify Library tool among stakeholders (e.g. by putting a link on our website);
	3. give permission for the inclusion of our name and logo on the Notify Library homepage to indicate our support for the initiative. YES NO
	It is noted that this statement does not extend to the provision of vigilance data or cases from our national vigilance system to the Notify Library. Regarding the provision of such data:
П	We give our permission for the publication of the provided didactic cases available on our National Vigilance
_	Report in the Notify Library;
	We wish that our National Vigilance Report stays confidential and that all the provided cases are referenced
	with a generic term, such as "CA EURO/AMRO/SEARO etc for the year " in order to define the WHO
	Region's origin and guarantee confidentiality ⁴ .
	CONTACT PERSON WHO WILL FILL IN Annex A and B
	Name:
	Surname:
	Role in the organization:
	Signature:
	Date:
	PLEASE RETURN THE COMPLETED FORM BY EMAIL TO NOTIFYLIBRARY@ISS.IT
	1 For Furnishing Computers Authorities who want their speed to star an effective in the ofference of an effective starting to the
	¹ For European Competent Authorities who want their report to stay confidential it will be referenced as: "European Union Annual Vigilance Report, year"

4.2 Notify Library - Record template

	NOTIFY LIBRARY Record template Annex B										
Free text - Title describing the case type	Occurrence classification according to the taxonomy	Medical product of human origin type according to the taxonomy. If you consider that new categories should be added to the taxonomy for more effective searching, please propose the new category in the NOTE field	Information on the time from the incident occurrence to its detection	Please enter the signs and symptoms that have been described in the references listed for this type of occurrence. In the case of adverse occurrences that involve 'Risk of Harm' rather than actual harm, you should describe how the occurrence was detected	information where quantitative data is available and relevant. Alternatively, descriptive information without quantitative data also have didactic value so please give some idea of frequency from your own experience and	Please enter free text to describe the methods used to confirm imputability for this type of occurrence. In the case of adverse occurrences that involve 'Risk of Harm' rather than actual harm, you should describe what is considered to be the root cause	Select a score for imputability - please refer to the imputability scale provided	These keywords refer to the Editorial Group Review (not to the keywords in the associated articles)	Add one or more references here that are good examples describing the occurrence type for that MPHO type. Please insert complete reference. Example: Tomasulo, P., Kamel, H., Bravo, M., James, R.C. and Custer, B. (2011). Interventions to reduce the vasovagal reaction rate in young whole blood donors. Transfusion 51(7): 1511-21	Use this space for didactic comments that will on the website appear when the case is uploaded	Use this field for internal communication only (<u>text not for</u> <u>publication</u>), as a message board for EG members and/or interaction with the NOTIFY team
Adverse occurrence description	Adverse occurrence type	MPHO type	Time to detection	Alerting signals, symptoms, evidence of occurrence	Estimated frequency	Demonstratio n of Imputability or Root cause	lmputability grade	Keywords	References	Expert comments for publication	NOTE

4.3 Notify Library - Adverse occurrence taxonomy

LEVEL 1LEVEL 2LEVEL 3LEVEL 4HIV HBV HCV HTLV West Nile Virus Influenza virus CMV LCMVHBV HCV HTLV West Nile Virus Influenza virus CMV LCMVViralLCMV EBV HEV Arenavirus Dengue HSV Rabies Parvovirus B19 Acinetobacter Alcaligenes Bacillus Bacteroides BartonellaHarm to a recipientInfectionInfectionInfection Eizabethkingia Eizabethkingia	ADVERSE OCCURRENCE TAXONOMY					
Harm to a recipient Infection Infection	LEVEL 1	LEVEL 2	LEVEL 3	LEVEL 4		
Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Bacterial Cershovia Derskovia Orientia	Harm to a	LEVEL 2	LEVEL 3 Viral	LEVEL 4HIVHBVHCVHTLVWest Nile VirusInfluenza virusCMVLCMVEBVHEVArenavirusDengueHSVRabiesParvovirus B19AcinetobacterAlcaligenesBacillusBacteroidesBartonellaBrucellaCitrobacterChlamydiaClostridiumEscherichiaElizabethkingiaEnterobacterHafniaKlebsiellaMorganellaMycobacteriumMycoplasmaOerskovia		

			Treponema
			Veillonella
			Acremonium
		Fungal	Apophysomyces
			Arthrographis
			Aspergillus
			Candida
			Coccidioides
			Cryptococcus
			Histoplasma
			Paecilomyces
			Rhodotorula
			CJD
		Prion	VCJD
			Acanthamoeba
			Balamuthia
	Parasitic	Parasitic	Clonorchis
			Echinococcus
			Plasmodium
			Schistosoma
			Strongyloides
			Toxoplasma
			Trypanosoma
		Wuchereria	
		Type not specified	
		Breast Cancer	
		CNS neoplasms	
		Colo-rectal carcinoma	
		Choriocarcinoma	
		Liver Cancer	
		Haematopoietic	_
		Lung	
		Melanoma	-
		Oesophageal	-
Malign	lancy	Oro-pharyngeal	-
		Ovarian Pancreatic	
			-
		Prostate Renal cell	-
		Sarcoma	-
		Thyroid	-
		Neuroendocrine	-
		Angiosarcoma	
		Urothelial tumor	
		Alloimmune	
Non-infecti	ous, Non-	Autoimmune	
malig	nant	Metabolic	
transmi	ssions	Genetic	
		Hypersensitivity/allergy	

		TRALI	_
		Allergic Reaction	-
		Acute Hemolytic Reaction	_
		Delayed Hemolytic Reaction	-
		Delayed Serologic Reaction	_
	nunological	Graft versus Host Disease	_
com	nplications	Post Transfusion Purpura (PTP)	_
		Rejection	_
		IgA deficiency	
			ABO immunisation
		Detrimental immunization	Rh immunisation
			HLA immunisation
		Hypotensive Reaction	
		Hypertensive Reaction	
		Acute Hemolytic Reaction - non-	
		immune	
		Delayed Hemolytic Reaction -	
		non-immune	
		TACO	
		TAD	
		Febrile Reaction	
			Citrate
		Toxicity	Potassium (hyperkalemia)
			DMSO
Mis	cellaneous		Ethlene oxide
com	nplications	Hemosiderosis	
	-	Graft failure	_
		Delayed engraftment	_
			Insufficient MPHO use
		Inappropriate clinical application	
			Eccessive MPHO use
		Undue exposure to	
		I ISK/IIILEI VEIILIOII	
		Surgical aita complicationa	
		Surgical site complications	_
		Catheter related complications	
		Catheter related complications Pulmonary complications	
		Catheter related complications Pulmonary complications Cardiovascular complications	
		Catheter related complications Pulmonary complications	
	nfection	Catheter related complications Pulmonary complications Cardiovascular complications	
		Catheter related complications Pulmonary complications Cardiovascular complications	
	nfection alignancy	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications	
Ma	alignancy	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications	
Ma Drug rel		Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome	
Ma Drug rel m to a	alignancy lated reactions	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications	
Ma Drug rel m to a	alignancy	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome	
Ma Drug rel m to a	alignancy lated reactions	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome	
Ma Drug rel onor Vasova	alignancy lated reactions agal Reactions	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome GCSF-related Local	
Ma Drug rel onor Vasova	alignancy lated reactions	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome GCSF-related Local Systemic	
Ma Drug rel onor Vasova Aller	alignancy lated reactions agal Reactions	Catheter related complications Pulmonary complications Cardiovascular complications Neurological complications Ovarian Hyperstimulation Syndrome GCSF-related Local	
		risk/intervention	

	Undue exposure to		
	risk/intervention		
	Excessive		
	collection/removal		
		Air embolism	
	Embolic Complications	Fat embolism	
		Thromboembolism	
		Cardiovascular	
		Neurological	
		Immunological	
		Metabolic	
	Miscellaneous	Insertion of needle	
	complications	Surgical site	
	Somphoations	Psychological	
		Catheterization/Intubation	
		Gastrointestinal	
		Pulmonary	
		Anesthetic agents	
	Procurement outside		
	legal framework		
Harm to a fetus or offspring	Genetic		
		Loss of highly matched or autologous MPHO	
	Loss	Loss of suitable organ(s)	
	2033	Loss of large quantity of unmatched MPHO	•
		Gamete mix-up	
	Mix-up	Embryo mix-up	
Risk of harm	•	Incorrect MPHO applied - no harm	
	Unsuitable MPHO released for clinical use - no harm		
	Wrong blood in tube - product not transfused		

4.4 Notify Library - MPHO taxonomy

	MPHO (Medical	Products of Human Origin) TAXO	NOMY
LEVEL 1	LEVEL 2	LEVEL 3	LEVEL 4
		Liver	7
		Heart	
		Kidney	
		Lung	-
		Pancreas	-
	0	Small bowel	-
	Organs		Heart lung
		Combined	Kidney pancreas
			Multivisceral
		Companyita tianua anafta	Hand
		Composite tissue grafts	Face
		Type not specified	
			Bone
			Cartilage
		Musculoskeletal	Osteochondral
			Tendon and ligament
			Meniscus
			Blood vessels
		Cardiovascular	Conduit
			Heart valves
			Pericardium
MBUO	Tissues	Ocular	Conjunctiva Cornea
МРНО			Limbal tissue
			Sclera
		Amniotic membrane	
		Other fetal membranes	-
		Dura mater	-
			-
		Larynx	-
		Nerve	_
		Parathyroiid glands	_
		Placenta	_
		Skin	
		Adipose tissue	
		Trachea	
		Umbilical cord tissue	
			Marrow
		HPC (hematopoietic progenitor	Apheresis
		cell)	Cord blood
	Cells		Whole blood
	Cells	Leukocytes	
		Chondrocytes	
		Hepatocytes	
		Pancreatic Islets	

		1
		Limbal cells
		Fibroblasts
		Adipocytes
		T-lymphocytes
		Keratinoctyes
		Mesenchymal stem cells
		Genetically modified cells
		Whole blood
	Blood	Red blood cells
Plead		Platelets
Biood		Plasma
		Cryoprecipitate
	Granulocytes	
Reproductive		Embryo
	Oocyte	
	Ovarian tissue	
	Testicular tissue	
		Sperm
		Combined
		Milk
Other		Fecal microbiota
		Topical products of human origin
		Plasma derivates
		Cell derived medicinal products
MPHO-deri		Tissue derived medicinal
medicinal pro	oducts	products
		Tissue and cell derived medicinal
		products

4.5 Imputability grade

IMPUTABILITY GRADE	CRITERIA FOR INFECTIOUS AND MALIGNANT TRANSMISSIONS ADAPTED FROM DTAC (1)	ADAPTED FROM EUSTITE-SOHO V&S (2) AND PROPOSED STANDARD DEFINITIONS FOR SURVEILLANCE OF NON INFECTIOUS ADVERSE TRANSFUSION REACTIONS (3)	ADAPTED FROM EUSTITE - SOHO V&S IN ASSISTED REPRODUCTIVE TECNOLOGIES (2)
Not Assessable	Insufficient data for imputability assessment	Insufficient data for imputability assessment	Insufficient data for imputability assessment
Excluded	Suspected transmission and fulfillment of at least one of the following conditions: - Clear evidence of an alternative cause; - The appropriate diagnostic tests performed have failed to document infection by the same pathogen in any recipient from the same donor; Laboratory evidence that the recipient was infected with the same pathogen or had a tumor before the application of organs, tissues or cells.	Conclusive evidence beyond reasonable doubt that the adverse occurrence can be attributed to causes other than the transfusion of blood components or transplantation of tissues/cells	Conclusive evidence beyond reasonable doubt for attributing to alternative causes than the ART process
Possible	Suspected transmission and: - Laboratory evidence of the pathogen or tumor in a single recipient, or Suspected transmission and: - Laboratory evidence of the pathogen or tumor in a single recipient or - Data suggest a transmission but are insufficient to confirm it.	The evidence is indeterminate for attributing the adverse occurrence either to the quality/safety of tissues/cells/blood components (for recipients), to the donation process (for donors), or to alternative causes	Evidence is indeterminate

Likely/Probable	 The following two conditions are met: Suspected transmission and Laboratory evidence of the pathogen or the tumor in a recipient. And it meets at least one of the following conditions: Laboratory evidence of the same pathogen or tumor in other recipients; Laboratory evidence of the same pathogen or tumor in the donor; If there is pre-transplant laboratory evidence, such evidence must indicate that the same recipient was negative for the pathogen involved before transplantation. 	The evidence is clearly in favour of attributing the adverse occurrence to the quality/safety of tissues/cells/blood components (for recipients) or to the donation process (for donors)	The evidence is in favour of attributing to the ART process
Definite/Certain; Proven	All the following conditions are met: - Suspected transmission; - Laboratory evidence of the pathogen or the tumor in a recipient; - Laboratory evidence of the same pathogen or tumor in other recipients (if multiple recipients); - Laboratory evidence of the same pathogen or tumor in the donor; - Laboratory evidence of the same pathogen or tumor in the donor;	The evidence is conclusive beyond reasonable doubt for attributing the adverse occurrence to the quality/safety of tissues/cells/ blood components (for recipients) or to the donation process (for donors)	Conclusive evidence beyond reasonable doubt for attributing to the ART process

(1) Uniform Definitions for Donor-Derived Infectious Disease Transmissions in Solid Organ Transplantation Christian Garzoni and Michael G. Ison Transplantation • Volume 92, Number 12, December 27, 2011

(2) SOHO V&S Guidance for Competent Authorities: Communication and Investigation of Serious Adverse Events and Reactions associated with Human Tissues and Cells

http://www.notifylibrary.org/sites/default/files/SOHO%20V%26S%20Communication%20and%20Investigation%20Guidance.pdf

(3) Proposed standard definitions for surveillance of non infectious adverse transfusion reactions, incorporating correction to TRALI definition (as adopted June 2013). ISBT Working Party on Haemovigilance

http://www.notifylibrary.org/sites/default/files/Proposed%20Definitions%20for%20surveillance%20of%20non%20infectious%20adverse%20transfusion%20reactions%2

4.6 Case examples

1683	Adverse occurrence description: Subject review: Donors with melanoma history and risk to ocular tissue recipients	1 reference				
	Adverse occurrence type:Risk of harm => Other					
	MPH0 type: Tissues => Ocular => Cornea					
	Time to detection: 2 months					
	Alerting signals, symptoms, evidence of occurrence: Recipient developed ocular melanoma within two months of surgery.					
	Estimated frequency: Rare; Review article written in response to single case report of melanoma transmission following keratolimbal allograft. No existing reports in					
	literature documenting melanoma transmission from corneal transplant. Based on the case report a moratorium on use of ocular tissue from donors with melanoma					
	(restricted from all use) and donors with metastatic solid tumors (not to be released for use of vascular components) was issued in February 2016 to be reviewed by					
	the Eye Bank Association of America in October 2016.					
	Demonstration of Imputability or Root cause: Donor had history of malignant melanoma.					
	Imputability grade:					
	Expert comments for publication: Article was written as a review at the time of active discussion regarding the appropriate response to the cited case report. It is					
	pointed out that donors with solid tumors constitute 30-40% of the ocular donor pool. In the case of melanoma, micrometastases raise concern for the possibility of					
	transmission, but in practice this has not been seen. Possible factors contributing to the absence of known transmissions include the avascular nature of cornea and					
	absence of immunosuppressive drugs. It is also noted that vascularized ocular components (such as keratolimbal allografts) also require immunosuppression and may					
	have tumor transmission risks more similar to solid organ transplants. The article discusses the need to balance restoring sight and patient safety in the difficult					
	setting of limited available evidence.					
	Keywords:					
	cornea transplantation cornea melanoma subject review keratolimbal metastasis exclusion criteria					

Record ID	Adverse occurrence	References
1705	Adverse occurrence description: Babesia duncani	3 reference
	Adverse occurrence type:Harm to a Recipient => Infection => Parasitic => Babesia	
	MPH0 type: Blood => Red blood cells	
	Time to detection: 130 days	
	Alerting signals, symptoms, evidence of occurrence: Immunosuppressed, multi-transfused (over a 10 year time period) recipient with sickle disease, autoinfarcted	
	spleen and several month history of declining health and increasing transfusion requirements, presented with frequent evaluations for weakness, fatigue, shortness	
	of breath and darkening of urine. Laboratory testing showed evidence of hemolysis with elevated bilirubin and reticulocytosis. Eventually he was diagnosed with	
	babesiosis when his blood smears were noted to contact intraerythrocytic parasites and Maltese cross forms in up to 12% of RBCs. Review of previous blood smears	
	showed intraerythrocytic parasites as early as 2 months prior. He was treated with RBC exchange and appropriate antibiotics. CDC investigation showed the source of	
	the infection to be Babesia duncani by DNA sequencing.	
	Estimated frequency: Rare; only 3 cases reported in literature (September 2016).	
	Demonstration of Imputability or Root cause: Investigation of 38 donors found one donor to be positive with B. duncani IFA, with titers as high as 1/4096. B. duncani	
	was also isolated by inoculating jirds (Mongolian gerbils) with a blood specimen taken more than 10 months after the index donation. Donor was healthy with extensive	
	history of outdoor hiking and mountain biking in Washington, British Columbia, Wyoming, Montana and Idaho. A history of tick bites was confirmed.	
	Imputability grade: 3 Definite/Certain/Proven	
	Expert comments for publication: This is a rare case of transfusion transmitted Babesia duncani diagnosed 4 months after the implicated transfusion from a donor	
	with known risk factors for tick exposure. Testing of the patient and donor confirmed B. duncani by DNA sequencing (recipient), IFA and inoculation of jirds (donor).	
	Keywords:	
	Babesia duncani RBC (red blood cell) multiple transfusions sickle cell disease hemolysis IFA (immunofluorescence antibody assay)	
	DNA sequencing tick exposure	
1496	Adverse occurrence description: Transfer of Selecive IgA Deficiency to a bone marrow recipient	2 reference
-	Adverse occurrence type:Harm to a Recipient => Non-infectious, Non-malignant transmissions => Genetic	
	MPHO type: Cells => HPC => Marrow	
	Time to detection: 3 months	
	Alerting signals, symptoms, evidence of occurrence: Relative lack of specific IgG2 anticarbohydrate antibodies in the donor and the recipient after transplant. IgG2	
	deficiency is considered as a prognostic marker for permanent lack of IgA.	
	Estimated frequency: Rare	
	Demonstration of Imputability or Root cause: Bone marrow transplant from HLA matched sibling with selective IgA deficiency, results in IgA deficiency in the	
	recipient. This recipient had normal IgA levels prior to transplant. Both the recipient and donor demonstrated the presence of IgA genes and it was speculated that the	
	IgA deficiency is manifested at stem cell level.	
	Imputability grade: 2 Probable	
	, , , , , , , , , , , , , , , , , , ,	

 Expert comments for publication: One of the few published case of transfer of selective IgA deficiency by marrow transplantation. There are other case reports that demonstrate correction of IgA deficiency in a marrow transplant recipient after transplantation from a donor who had no IgA deficiency

 Keywords:
 IgA deficiency
 bone marrow transplantation

 IgA deficiency
 bone marrow transplantation
 stem cell

4.6.1 Each record in the Notify Library describes a type of adverse occurrence for one type of substance

	Reference ID	Reference	
	1561	Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor, Tugwell, B. D., Patel P. R., Williams I. T., Hedberg K., Chai F., Nainan O. V., Thomas A. R., Woll J. E., Bell B. P., and Cieslak P. R., Ann Intern Med, 37196, Volume 143, Issue 9, p.648 - 54,	
		(2005) 559 - Hepatitis C Virus 0 561 - Hepatitis C Virus 0 563 - Hepatitis C Virus 0 564 - Hepatitis C Virus 0 564 - Hepatitis C Virus 0	(HCV) - Kidney s (HCV) - Tendon or Ligame

		1803	Transmission of human immunodeficiency virus and hepatitis C organ donor to four transplant recipients., Ison, M. G., Llata E., Conover C Gerber S. I., Grigoryan A., Heneine W., Millis J. M., Simon D. M., Teo C. G., et al., Jun, Y	. S., Friedewald J. J.,	6 occurrences
			United States, p.8, (2011)	555 - Hepatitis C Virus (HCV) - Liver 558 - Hepatitis C Virus (HCV) - Heart 560 - Hepatitis C Virus (HCV) - Kidney 568 - Human Immunodeficiency Virus (HIV) - Liver	
				508 - Human Immunodeficie 573 - Human Immunodeficie 576 - Human Immunodeficie	ncy Virus (HIV) - Heart

4.6.2 CAs submitting records for inclusion in the Notify Library's database should make two records for the same type of occurrence with the same MPHO if they consider that are substantially different from each other in terms of cause, method of confirmation of imputability or any other factor that is considered to have major didactic value.

Record ID	Adverse occurrence	[1761] Parrish, C.M.; O'Day, I Acanthamoeba keratitis fo factors. 1991; 13 (Suppl 5) :	llowing penetrating keratoplasty in a patient without other identi	Fiable risk
3	Adverse occurrence description: Acanthamoeba Irefa Adverse occurrence type:Harm to a Recipient +> Infection +> Parasitic +> Acanthamoeba Irefa MPHO type: Tissues +> Dcular +> Cornea Time to detection: 3 weeks Alerting signals, symptoms, evidence of occurrence: 74 yr old Female. PK for bullous keratopathy followed by retrocorneal membrane, glaucoma 6 months later Lexamcretained Decemet's membr, stromal edema, epith.haze, punctate epithelial erosions). Regrafted (PK#2): Explanted PK#1 cornea: no Acanthamoeba 3 weeks Later developed inferior stromal keratitis, epithelial defect, hypopyon. Regrafted again (PK#3): Explanted PK#2 cornea Acanthamoeba cysts and trophozoites. PK using other cornea from donor did not result in infection. PK#3 progressed to enucleation. Histology of cornea of PK#3 showed Acanthamoeba cysts Estimated frequency: N/A Demonstration of Imputability or Root cause: Level Possible ransmission by PK. No other environmental or patient risk factors. No infection from mate cornea. L287J Camposampiero, D.; Caramello, G.; Indemini, P.; Gerten, G.; Franch, A.; Birattari, F.; Donisi, PM; Paolin, A.; Ferrari, S.; Ponzin, D. Metres occurrence type:Harm to a Recipient +> Infection +> Parasitic +> Acanthamoeba L287J Camposampiero, D.; Caramello, G.; Indemini, P.; Gerten, G.; Franch, A.; Birattari, F.; Donisi, PM; Paolin, A.; Ferrari, S.; Ponzin, D. Time to detection: I week Adverse occurrence: 30 yr old male penetrating keratoplasty (PK) for keratoconus. After one week developed eye pain, cilary injection, graft edema, keratitic precipitates. Regrafted after I month. Excised button: Acanthamoeba cysts in stroma. Recurred again, had 3rd graft aft			1reference
				D. rence

4.6.3 Where one record describes many cases, the experts should summarise the findings using ranges, averages, etc.

Record ID	Adverse occurrence	[4264] Mortensen, E.; Hellinger, W.; Keller, C.; Cowan, L.; Shaw, T.; Hwang, S.; Pegues, D.; Ahmedov, S.; Salfinger, M.; Bower, W. Three cases of donor-derived pulmonary tuberculosis in lung transplant recipients and review of 12 previously reported cases: opportunities for early diagnosis and prevention. //Transpl Infect Dis 2014; 16 (D):67 - 75		
1309	shortness of breath and bilateral pulmonary infiltrates with a n BAL showing AFB and culture grew M. tuberculosis with a new after bilateral lung transplant, a routine BAL showed growth of AFB and a new right upper lobe pulmonary nodule. Estimated frequency: N/A Demonstration of Imputability or Root cause: Three lung re organ donors had evidence of TB. Each of the three patient's T identical to that found in a TB outbreak near where the donor! donors. This data does not exclude community acquisition by t Imputability grade: I Possible Expert comments for publication: Keywords: Mycobacterium tuberculosis TB (tuberculosis) Img	Bacterial => Mycobacterium Five months after lung transplant, the recipient developed 2 weeks of malaise followed by acute iodule and patchy infiltrate. Case 2: Two months after lung transplant, the asymptomatic patient had a right upper lobe pulmonary nodule and atelectasis that cavitated the next month. Case 3: Three months pan-sensitive M. tuberculosis. The patient was asymptomatic. At four months postop BAL showed 4- cipients were TST-negative prior to transplant but developed active TB; whereas, none of the three 'B isolates were identical with TB found in the country where two donors had lived (case 1 and 3), or had lived and had been imprisoned (case 2). This is indirect evidence of acquiring TB from the organ the recipient.	Ireference	

[1823] Reichard, K.K.; Zhang, O.Y.; Sanchez, L.; Hozier, J.; Viswanatha, D.; Foucar, K. Acute Myeloid Leukemia of Donor Origin After Allogeneic Bone Marrow Transplantation for Precursor T-Cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature 2006; 81 (3):7
[666] Hertenstein, B.; Hambach, L.; Bacigalupo, A.; Schmitz, N.; McCann, S.; Slavin, S.; Gratwohl, A.; Ferrant, A.; Elmaagacli, A.; Schwertfeger, R.; Locasciulli, A.; Zander, A.; Bornhauser, M.; Niederwieser, D.; Ruutu, T.

Development of leukemia in donor cells after allogeneic stem cell transplantation--a survey of the European Group for Blood and Marrow Transplantation (EBMT) Haematologica 2005; 90 (7) :969 - 75 Record ID Adverse occurrence 681 Adverse occurrence description: Acute myeloid leukemia (AML) 2 references Adverse occurrence type:Harm to a Recipient => Malignancy => Haematopoietic MPH0 type: Cells => HPC => Marrow Time to detection: 17 [4-164] months Alerting signals, symp ce of occurrence: Elevated blood counts; anemia; thrombopenia. 17 (4-164) months from SCT Estimated frequency: 7/18489 Demonstration of Imputability or Root cause: Case 1: cytogenetics and molecular marker. Case 2: Fluorescence in-situ hybridization (FISH) analysis showed the AML to be of donor origin (i.e., karyotypically female) with an 11q23 (mixed lineage leukemia (MLL) gene) translocation, while the original T-ALL exhibited a male karyotype with abnormalities of chromosomes 6, 8, and a t(10;14)(q24;q11.2). Subsequent molecular short tandem repeat studies confirmed the AML to be of donor origin. Imputability grade: Expert comments for publication: Keywords: cytogenetics anemia FISH (fluorescence in situ hybridization) karyotype AML (acute myeloid leukemia) allogeneic